Back to Journals » Journal of Hepatocellular Carcinoma » Volume 2

Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy

Authors Jang JH, Lee J, Hong JT, Jin Y

Received 28 February 2015

Accepted for publication 28 July 2015

Published 2 September 2015 Volume 2015:2 Pages 123—129

DOI https://doi.org/10.2147/JHC.S44380

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Ahmed O Kaseb


Ji Hye Jang, Jin-Woo Lee, Ji Taek Hong, Young-Joo Jin

Division of Gastroenterology and Hepatology, Inha University School of Medicine and Hospital, Incheon, Republic of Korea

Abstract: Transarterial chemoembolization (TACE) is the standard treatment for patients with Barcelona Clinic Liver Cancer-intermediate stage hepatocellular carcinoma (HCC). The concept of drug-eluting bead TACE builds on the rationale of intratumoral drug delivery, and drug-eluting bead TACE has been shown to provide consistent and reliable results and to significantly diminish systemic drug exposure, liver toxicity, and drug-related adverse events as compared with conventional TACE. Based on the belief that combinations of TACE and other local or systemic therapies have several theoretical advantages, many clinical trials have been conducted to evaluate the effectiveness of TACE in combination with local treatment such as radiofrequency ablation or radiotherapy, and systemic therapy such as sorafenib or another molecular therapy. TACE has also been used as a preoperative adjuvant chemotherapy in patients with HCC to improve survival and as a bridging therapy before liver transplantation to downstage HCC. In the present evidence-based review, the authors summarize the current status of these transcatheter arterial embolic therapies in HCC.

Keywords: transarterial chemoembolization (TACE), hepatocellular carcinoma (HCC), evidence-based review

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]